NL301118I2 - Fostemsavir - Google Patents
FostemsavirInfo
- Publication number
- NL301118I2 NL301118I2 NL301118C NL301118C NL301118I2 NL 301118 I2 NL301118 I2 NL 301118I2 NL 301118 C NL301118 C NL 301118C NL 301118 C NL301118 C NL 301118C NL 301118 I2 NL301118 I2 NL 301118I2
- Authority
- NL
- Netherlands
- Prior art keywords
- methyl
- fostemsavir
- dioxoethyl
- phosphonooxy
- hpmc
- Prior art date
Links
- SWMDAPWAQQTBOG-UHFFFAOYSA-N fostemsavir Chemical compound C1=2N(COP(O)(O)=O)C=C(C(=O)C(=O)N3CCN(CC3)C(=O)C=3C=CC=CC=3)C=2C(OC)=CN=C1N1C=NC(C)=N1 SWMDAPWAQQTBOG-UHFFFAOYSA-N 0.000 title abstract 2
- 229950010812 fostemsavir Drugs 0.000 title 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/062—Organo-phosphoranes without P-C bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9413108P | 2008-09-04 | 2008-09-04 | |
| PCT/US2009/055820 WO2010028108A2 (en) | 2008-09-04 | 2009-09-03 | Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301118I1 NL301118I1 (enExample) | 2021-07-23 |
| NL301118I2 true NL301118I2 (nl) | 2022-02-22 |
Family
ID=41726353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301118C NL301118I2 (nl) | 2008-09-04 | 2021-07-26 | Fostemsavir |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20100056540A1 (enExample) |
| EP (1) | EP2323633B1 (enExample) |
| JP (1) | JP5638527B2 (enExample) |
| CN (1) | CN102143739B (enExample) |
| AT (1) | ATE550016T1 (enExample) |
| CA (1) | CA2735008C (enExample) |
| CY (1) | CY1112816T1 (enExample) |
| DK (1) | DK2323633T3 (enExample) |
| ES (1) | ES2383149T3 (enExample) |
| HR (1) | HRP20120441T1 (enExample) |
| NL (1) | NL301118I2 (enExample) |
| PL (1) | PL2323633T3 (enExample) |
| PT (1) | PT2323633E (enExample) |
| SI (1) | SI2323633T1 (enExample) |
| SM (1) | SMT201200029B (enExample) |
| WO (1) | WO2010028108A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9248139B2 (en) * | 2011-12-21 | 2016-02-02 | Bristol-Myers Squibb Company | Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023265A (en) * | 1990-06-01 | 1991-06-11 | Schering Corporation | Substituted 1-H-pyrrolopyridine-3-carboxamides |
| US5124327A (en) * | 1991-09-06 | 1992-06-23 | Merck & Co., Inc. | HIV reverse transcriptase |
| JP2686215B2 (ja) * | 1993-04-28 | 1997-12-08 | 信越化学工業株式会社 | 徐放性錠剤 |
| US5424329A (en) * | 1993-08-18 | 1995-06-13 | Warner-Lambert Company | Indole-2-carboxamides as inhibitors of cell adhesion |
| CA2173818A1 (fr) * | 1996-04-10 | 1997-10-11 | Francois Chouinard | Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose |
| US6476034B2 (en) * | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
| US20020061892A1 (en) * | 2000-02-22 | 2002-05-23 | Tao Wang | Antiviral azaindole derivatives |
| AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US6825201B2 (en) * | 2001-04-25 | 2004-11-30 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| US20040063744A1 (en) * | 2002-05-28 | 2004-04-01 | Tao Wang | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
| US7745625B2 (en) * | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US20060167044A1 (en) * | 2004-12-20 | 2006-07-27 | Arnaiz Damian O | Piperidine derivatives and their use as anti-inflammatory agents |
| US7601715B2 (en) * | 2005-06-22 | 2009-10-13 | Bristol-Myers Squibb Company | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
| US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
| US7807671B2 (en) * | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
-
2009
- 2009-09-03 PT PT09792207T patent/PT2323633E/pt unknown
- 2009-09-03 HR HRP20120441AT patent/HRP20120441T1/hr unknown
- 2009-09-03 DK DK09792207.4T patent/DK2323633T3/da active
- 2009-09-03 JP JP2011526181A patent/JP5638527B2/ja active Active
- 2009-09-03 EP EP09792207A patent/EP2323633B1/en active Active
- 2009-09-03 US US12/553,310 patent/US20100056540A1/en not_active Abandoned
- 2009-09-03 SI SI200930268T patent/SI2323633T1/sl unknown
- 2009-09-03 AT AT09792207T patent/ATE550016T1/de active
- 2009-09-03 PL PL09792207T patent/PL2323633T3/pl unknown
- 2009-09-03 CA CA2735008A patent/CA2735008C/en not_active Expired - Fee Related
- 2009-09-03 ES ES09792207T patent/ES2383149T3/es active Active
- 2009-09-03 WO PCT/US2009/055820 patent/WO2010028108A2/en not_active Ceased
- 2009-09-03 CN CN200980135118.2A patent/CN102143739B/zh not_active Expired - Fee Related
-
2012
- 2012-06-01 CY CY20121100500T patent/CY1112816T1/el unknown
- 2012-06-19 SM SM201200029T patent/SMT201200029B/xx unknown
-
2014
- 2014-12-11 US US14/567,554 patent/US20150158891A1/en not_active Abandoned
-
2021
- 2021-07-26 NL NL301118C patent/NL301118I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2323633E (pt) | 2012-05-29 |
| PL2323633T3 (pl) | 2012-08-31 |
| JP2012502042A (ja) | 2012-01-26 |
| ATE550016T1 (de) | 2012-04-15 |
| US20100056540A1 (en) | 2010-03-04 |
| ES2383149T3 (es) | 2012-06-18 |
| DK2323633T3 (da) | 2012-07-09 |
| HRP20120441T1 (hr) | 2012-06-30 |
| US20150158891A1 (en) | 2015-06-11 |
| JP5638527B2 (ja) | 2014-12-10 |
| EP2323633B1 (en) | 2012-03-21 |
| WO2010028108A2 (en) | 2010-03-11 |
| CA2735008C (en) | 2016-11-29 |
| NL301118I1 (enExample) | 2021-07-23 |
| EP2323633A2 (en) | 2011-05-25 |
| CN102143739A (zh) | 2011-08-03 |
| SMT201200029B (it) | 2012-09-07 |
| CA2735008A1 (en) | 2010-03-11 |
| SI2323633T1 (sl) | 2012-07-31 |
| CN102143739B (zh) | 2014-12-17 |
| CY1112816T1 (el) | 2016-02-10 |
| WO2010028108A3 (en) | 2010-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2459393B (en) | Novel capsule formulation for the proton pump inhibitor omeprazole | |
| PL1899329T3 (pl) | Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych | |
| NO20090738L (no) | Tilveiebringelse av EP2 agonister, fremgangsmate for fremstilling derav, farmasoytiske sammensetninger inneholdende disse forbindelser og fremgangsmater for anvendelse av forbindelsene og sammensetningene for a senke intraokkulaert trykk og behandle glaukom | |
| ATE479687T1 (de) | Kinaseinhibitoren | |
| TNSN08178A1 (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
| CY1115971T1 (el) | Νεο παραγωγο φαινυλ ιμιδαζολιου ως αναστολεας ενζυμου pde10a | |
| MX2008011976A (es) | Composiciones farmaceuticas. | |
| CL2007002167A1 (es) | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. | |
| DK2010190T3 (da) | Farmaceutisk opløsningsformulering til tryksatte, dosisregulerede inhalatorer | |
| IL191769A0 (en) | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine | |
| BRPI0821004A8 (pt) | Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste | |
| TN2011000207A1 (en) | Akt and p70 s6 kinase inhibitors | |
| CL2009000906A1 (es) | Compuestos derivados de 4-imidazolil y 4-triazolil de 2-(6-(4-cicloalquilpiperazin-1-il)pirimidin-4-il)-1h-pirazol-3(2h)ona inhibidores de hif-prolil-4-hidroxilasas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de enfermedades cardiovasculares, renales y hematologicas. | |
| CL2009001346A1 (es) | Compuestos derivados heterociclicos, inhibidores de la adn girasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion bacteriana. | |
| WO2010130773A3 (en) | Benzoxazolone derivatives as aldosterone symthase inhibitors | |
| MX2008013040A (es) | Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1. | |
| BRPI0518203A2 (pt) | mÉtodos para preparaÇço de compostos indazol | |
| MX2007004248A (es) | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. | |
| NL301118I2 (nl) | Fostemsavir | |
| CL2011000292A1 (es) | Compuestos derivados de enfumafungina y sus sales farmaceuticamente aceptables, como inhibidores de (1,3)-beta-d-glucano sintasa; composicion farmaceutica; y uso para tratar una infeccion fungica. | |
| AR058047A1 (es) | Administracion de inhibidores de dipeptidil peptidasa | |
| AR048672A1 (es) | Tabletas de desintegracion que comprenden licarbazepina | |
| UA94953C2 (en) | Ep2 agonists | |
| HK1137147B (en) | Novel capsule formulation for the proton pump inhibitor omeprazole | |
| TW200833325A (en) | Pharmaceutical composition comprising ascorbic acid |